October 15, 2004

For Immediate Release

FOOTHILL RANCH, CA -- Current Awareness in the Understanding of Cardiovascular Disease and the Options for Treatment Revealed in MedMarket Diligence Report

Atherosclerotic vascular disease is among the most frequent causes of death worldwide. It is the consequence of complex interactions between many pathogenic mechanisms including alterations in lipoprotein metabolism, fibrinolysis, coagulation, and vessel-wall structure. Current therapeutic strategies have historically concentrated mainly on lowering low-density lipoprotein (LDL) cholesterol and an impressive reduction in the risk for cardiovascular morbidity and mortality has been achieved. Inflammatory mechanisms are more and more recognized to play an important role in vascular disease as inflammatory markers correlate with prognosis in acute and chronic coronary artery disease. This shift in focus comes as a byproduct of extensive research in vascular biology which has clearly demonstrated that inflammation can play a vital role in the initiation, maintenance and/or progression of atherosclerosis.

MedMarket Diligence, in conjuction with Cheirologic Partners, has released a report on "Cardiovascular Disease:  A Review of Biomarkers, Surrogate Endpoints and Therapeutic Options," which reviews both the current clinical understanding of the etiologies of cardiovascular disease and the current and emerging markets associated with screening and treatment options.  The report is detailed at www.mediligence.com/rpt-c225.htm.

About MedMarket Diligence

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the “MedMarkets” newsletter, a monthly analysis of the market implications of new medical technology and dedicated reports on technology markets. For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit http://www.mediligence.com.